Comments
Dr Reddy’s Laboratories on Monday reported a consolidated loss of ₹569.7 crore for the quarter ended December 2019.
The company had posted a profit of ₹485.2 crore in the year-ago period, Dr Reddy’s Laboratories said in a BSE filing.
The consolidated revenues of the company in the October-December period increased to ₹4,383.8 crore, over ₹3,850 crore in the year-ago period.
“The current quarter performance has been good across all our businesses and we achieved strong earnings before interest, taxes, depreciation and amortisation (EBITDA) margins,” the company’s Co-Chairman and MD GV Prasad said in a statement.
The profits were impacted due to trigger-based impairment charge taken on a few products including gNuvaring, he said, adding that the company continues to focus on execution and has made significant progress on quality systems and operational efficiencies.
The shares of Dr Reddy’s Laboratories were trading at ₹3,088.40 a piece on BSE, up 1.99 per cent from the previous close.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.